top of page


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
03/09/2026 FDA granted Fast Track Designation to YUTREPIA® for the treatment of Raynaud's phenomenon associated with systemic sclerosis. FDA granted Fast Track Designation to YUTREPIA® for the treatment of Raynaud's phenomenon associated with systemic sclerosis. (Ref) Liquidia Corporation announced that the US FDA had granted Fast Track designation to YUTREPIA® (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-R
decodeMR Team
Sep 41 min read


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
06/03/2026 The US FDA approved deucravacitinib for the treatment of patients with active PsA Aisa Pharma announced the results from its Phase 2 trial of AISA-021 in patients with SSc RP The US FDA approved deucravacitinib for the treatment of patients with active PsA ( Ref ) BMS announced that the US FDA had approved Sotyktu® (deucravacitinib; TYK2 inhibitor) for the treatment of adult patients with active psoriatic arthritis (PsA) The approval was based on positive results f
decodeMR Team
Mar 91 min read
bottom of page